Your monthly newsletter from the "better way to access market intelligence" people at medintellibase.com MedIntelliBase NewsTips... A Better Way...to stay up-to-date Highlights Late-Breaking Updates
New MedIntelliBase™ Alerts - Stay up-to-date by email on relevant industry events and announcements as they occur
Stay tuned... |
|||||
| Table of Contents Late Breaking News from the World Congress of Cardiology (WCC) 2006 -- Cardiovascular & Endovascular Therapeutics MIB MarketTracks
Fun Fact of the Month
MedIntelliBase MarketTracks and Alerts>> A Better Way...to access market Intelligence
|
|||||
| Cardiovascular & Endovascular Therapeutics MarketTracks - The Next Phase is pleased to present our NewsTips subscribers two thought-provoking excerpts from its coverage of the World Congress of Cardiology (WCC) 2006 conference in Barcelona, Spain from September 2-6, 2006: BASKET Study More details available to our subscribers Dr. Christoph Kaiser of Basel, Switzerland presented 18-month results from the Basel Stent Cost-effectiveness Trial--Late Thrombotic Events (BASKET), which suggest that using drug-eluting stents may not lead to optimal benefits in vessels with a diameter larger than 3mm. The study randomized 826 consecutive patients in a 2:1 manner respectively to drug-eluting stents (DES) or bare metal stents (BMS). 18-month follow-up was conducted and documented the occurrence of major adverse cardiac events (MACE). Dr. Kaiser reported that overall event rates were low including death/MI, non-infarct related target vessel revascularization, and MACE. In an analysis of patients with and without bypass graft interventions and small vessel stenting (<3.0mm), a highly significant benefit was observed with the use of DES compared to BMS. For the remainder of patients with vessels larger than 3.0mm, no benefits were observed when using DES versus BMS. According to Dr. Kaiser these findings challenge the popular idea that, regardless of baseline characteristics, all patients should receive DES. WAVE Study More details available to our subscribers The addition of warfarin to aspirin therapy in the treatment of peripheral arterial disease (PAD) did not benefit patients in the Warfarin Antiplatelet Vascular Evaluation (WAVE) study. According to Dr. Sonia Anand (McMaster University, Hamilton, ON), bleeding complications associated with the use of warfarin in addition to aspirin neutralized any potential benefits. Patients who received warfarin plus aspirin were at a significantly higher risk of life-threatening bleeds than those who received aspirin therapy alone. The WAVE study was conducted in 80 centers and seven countries. Nearly 2000 PAD patients were randomized to aspirin plus warfarin or aspirin alone. In both groups, therapy was titrated to reach INR levels of 1.8 to 3.5. The two primary endpoints included cardiovascular death, MI, and stroke; and CV death, MI, stroke, and severe ischemia in the coronary or peripheral arteries. Life-threatening bleeding and moderate bleeding were the two safety endpoints. No significant benefit in favor of the two-drug regimen was observed in either of the efficacy endpoints. Furthermore, the combination of warfarin and aspirin was associated with a significantly increased risk of moderate and life-threatening bleeds, and a 15-fold risk of hemorrhagic stroke. These results demonstrate the need for further studies with better antithrombotics in PAD, such as aspirin plus oral factor Xa inhibitors or thrombin blockers. Return to Top |
|||||
Link of the Month
|
|||||
Fun Fact of the Month
|
|||||
| MedIntelliBase MarketTracks and Alerts >> A Better Way ... Does this "quest for Market Intelligence" sound familiar?
MedIntelliBase MarketTracks and Alerts give you A Better Way:
MIB Alerts
***Late breaking as well as archived information on pivotal trials and registries and emerging technologies remains available to you within our databases for years to come - enabling you to track years of developments and history so you and your team do not repeat past mistakes. Interested? Want to know more? Want a trial? Contact us for:
|
|||||
| More Information Available at www.MedIntelliBase.com You can find more in-depth information about the details noted above and many other technologies and clinical studies we have been tracking over the years in our MedIntelliBase MarketTracks >> visit our website at www.MedIntelliBase.com We will be pleased to help you find the critical intelligence you need to make informed product development and business investment decisions. Contact us directly... Return to Top |
|||||
FYI:
Editor: Vicky Hunsicker Sanko The Next Phase Publishing** Mobile - 206/669-3053 Phone - 425/869-8724 Toll Free - 800/390-2756 Fax - 425/869-9397 Assistant Editor & Market Research Analyst: Tyler Mittleider The Next Phase Publishing** Phone - 425/894-4148 Fax - 425/869-9397 Market Research Analyst: Jordan Zornes The Next Phase Publishing** Phone - 425/894-4147 Fax - 425/869-9397 ** A division of Next Phase® Consultancy, Inc. © The Next Phase® Consultancy, Inc. 2006. All rights reserved. Return to Top |